Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Ultra-rare disease specialist Ultragenyx Pharmaceutical has inked a deal with GeneTx Biotherapeutics in relation to the antisense oligonucleotide GTX-102. 16 August 2019
Biotechnology
GeneCentric Therapeutics has acquired the data analysis and biomarker development firm Select ImmunoGenomics. Both companies are based in North Carolina, USA. 16 August 2019
Biotechnology
The US Food and Drug Administration has granted accelerated approval for Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). 16 August 2019
Biotechnology
Eli Lilly has released data showing that its Taltz (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase IV IXORA-R study, which evaluated the efficacy and safety of Taltz versus rival drug Tremfya (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). 15 August 2019
Biotechnology
Two senior executives at Novartis' AveXis unit are being shown the door as the firm faces accusations from the US regulator it was aware of data manipulation before it filed for gene therapy Zolgensma (onasemnogene abeparvovec-xioi). 15 August 2019
Biotechnology
Australian biotech CSL Limited saw its shares rise 6.6% to A$234.00 today, after it posted revenue of $8,539 million, up 7.9%, for the 12 months ended June 30, 2019. CSL is Australia largest health business specializing in immunotherapies and vaccines for life-threatening diseases. 14 August 2019
Biotechnology
A week after presenting compelling Lynparza (olaparib) results in prostate cancer, AstraZeneca and Merck & Co have completed the data set in support of its use across advanced ovarian cancer disease maintenance settings. 14 August 2019
Biotechnology
Adding to good previous earlier-stage clinical data, Regeneron Pharmaceuticals today announced positive pivotal Phase III results for evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody, in patients with homozygous familial hypercholesterolemia (HoFH). 14 August 2019
Biotechnology
Danish dermatology specialist LEO Pharma says it has acquired the exclusive rights to develop and market brodalumab (marketed as Kyntheum in the European Union and Siliq in other regions) for the treatment of moderate-to-severe psoriasis outside of Europe through a new sub-licensing agreement with Bausch Health. 14 August 2019
Biotechnology
If the accusation of withholding information over Zolgensma (onasemnogene abeparvovec-xioi) is the first major test for Novartis chief executive Vasant Narasimhan, then it is increasingly looking like a big one. 14 August 2019
Biotechnology
The US Food and Drug Administration has granted Breakthrough Therapy designation (BTD) for Calquence (acalabrutinib) as a monotherapy treatment for adult patients with chronic lymphocytic leukemia (CLL), one of the most common types of leukemia in adults. 14 August 2019
Biotechnology
China’s medicines regulator has called for greater implementation of the Vaccine Administration Law, urging drug regulatory departments to put promoting awareness of the law “at the top of their agenda.” 13 August 2019
Biotechnology
A resounding success in the Phase III INVICTUS study sent shares in East Coast, USA-based Deciphera Pharmaceuticals climbing around 80% on Tuesday. 13 August 2019
Biotechnology
The Janssen and AbbVie partnered drug Imbruvica (ibrutinib) has now nabbed five European Commission (EC) approvals in as many years, as its use was broadened in two indications. 13 August 2019
Biotechnology
Positive growth from tablet products propelled allergy immunotherapy specialist ALK Abello to a strong performance in the second quarter of 2019, with total revenues up 9% at 785 million Danish kroner ($117 million). 13 August 2019
Biotechnology
Struggling rare diseases company Novelion Therapeutics admitted further difficulties on Tuesday related to its outgoing Aegerion subsidiaries. 13 August 2019
Biotechnology
Positive results for Eli Lilly’s IL-17 blocker Taltz (ixekizumab) in the Phase IV IXORA-R study will help support its use for people living with moderate to severe plaque psoriasis. 13 August 2019
Biotechnology
AskBio, which calls itself the world’s foremost clinical stage and gene therapy platform company, has acquired Synpromics, the self-styled leader in gene control synthetic promoter technology, bioinformatics and intelligent data-driven design that enables more precise cell targeting and gene expression. 13 August 2019
Biotechnology
US biotech XOMA Corporation could be in line for further future royalty and milestone payments after expanding its portfolio of partnered assets. 13 August 2019
Biotechnology
Ireland-headquartered Jazz Pharmaceuticals late Monday announced the acquisition of clinical-stage biotech firm Cavion, through a merger with a Jazz subsidiary. 13 August 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze